fascinating New York Times articlePosted by elliott on 6/03/04 at 14:40 (151910)
Not sure if the link to an exclusive article in today's business section of the NYT will work for you, especially if you are not registered for the NYT online:
Here's a brief summary:
A drug company conducted two trials testing Paxil, a popular anti-depressant, to see if it would aid depressed children: the first was conducted in America, the second in numerous other countries. The one in America showed positive results; the one abroad, completed shortly thereafter, indicated no more benefit than a sugar pill. The scandal is, the first study was published, but not the second. An outside researcher who was part of the study spilled the beans at a medical conference.
The article goes on to say that when a drug is submitted to the FDA for approval, *all* relevant studies, even unpublished ones, must always be and indeed were in this case, submitted to the FDA, which as a matter of policy never reveals such things to the public. Well, Federal regulators are now reassessing such anti-depressant drugs. The New York State attorney general is suing the drug company for consumer fraud. There is a discussion about if there should be a public trials registry reporting on *all* trials, not just those published.
Re: fascinating New York Times articleDorothy on 6/03/04 at 15:06 (151913)
Great information, Elliott. Thank you.